Literature DB >> 25321320

Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Gerard J Criner1, Jean Bourbeau2, Rebecca L Diekemper3, Daniel R Ouellette4, Donna Goodridge5, Paul Hernandez6, Kristen Curren7, Meyer S Balter8, Mohit Bhutani9, Pat G Camp10, Bartolome R Celli11, Gail Dechman12, Mark T Dransfield13, Stanley B Fiel14, Marilyn G Foreman15, Nicola A Hanania16, Belinda K Ireland17, Nathaniel Marchetti18, Darcy D Marciniuk19, Richard A Mularski20, Joseph Ornelas3, Jeremy D Road21, Michael K Stickland22.   

Abstract

BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumulated about the prevention of acute exacerbations.
METHODS: In recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. Three key clinical questions developed using the PICO (population, intervention, comparator, and outcome) format addressed the prevention of acute exacerbations of COPD: nonpharmacologic therapies, inhaled therapies, and oral therapies. We used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion.
RESULTS: The AECOPD Guideline is unique not only for its topic, the prevention of acute exacerbations of COPD, but also for the first-in-kind partnership between two of the largest thoracic societies in North America. The CHEST Guidelines Oversight Committee in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD.
CONCLUSIONS: This guideline is unique because it provides an up-to-date, rigorous, evidence-based analysis of current randomized controlled trial data regarding the prevention of COPD exacerbations.

Entities:  

Mesh:

Year:  2015        PMID: 25321320      PMCID: PMC4388124          DOI: 10.1378/chest.14-1676

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  266 in total

Review 1.  Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Authors:  Sally Spencer; Charlotta Karner; Christopher J Cates; David J Evans
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  AGREE II: advancing guideline development, reporting and evaluation in health care.

Authors:  Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger
Journal:  CMAJ       Date:  2010-07-05       Impact factor: 8.262

3.  Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

Authors:  François Maltais; Bartolome Celli; Richard Casaburi; Janos Porszasz; Diana Jarreta; Beatriz Seoane; Cynthia Caracta
Journal:  Respir Med       Date:  2010-12-22       Impact factor: 3.415

4.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Authors:  Paul W Jones; Dave Singh; Eric D Bateman; Alvar Agusti; Rosa Lamarca; Gonzalo de Miquel; Rosa Segarra; Cynthia Caracta; Esther Garcia Gil
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

5.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

6.  N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.

Authors:  R Pela; A M Calcagni; S Subiaco; P Isidori; A Tubaldi; C M Sanguinetti
Journal:  Respiration       Date:  1999 Nov-Dec       Impact factor: 3.580

Review 7.  Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Authors:  Y Lacasse; R Goldstein; T J Lasserson; S Martin
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 8.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Toby J Lasserson; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

9.  The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

Authors:  N Mittmann; L Kuramoto; S J Seung; J M Haddon; C Bradley-Kennedy; J M Fitzgerald
Journal:  Respir Med       Date:  2007-12-20       Impact factor: 3.415

10.  An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation.

Authors:  Martijn A Spruit; Sally J Singh; Chris Garvey; Richard ZuWallack; Linda Nici; Carolyn Rochester; Kylie Hill; Anne E Holland; Suzanne C Lareau; William D-C Man; Fabio Pitta; Louise Sewell; Jonathan Raskin; Jean Bourbeau; Rebecca Crouch; Frits M E Franssen; Richard Casaburi; Jan H Vercoulen; Ioannis Vogiatzis; Rik Gosselink; Enrico M Clini; Tanja W Effing; François Maltais; Job van der Palen; Thierry Troosters; Daisy J A Janssen; Eileen Collins; Judith Garcia-Aymerich; Dina Brooks; Bonnie F Fahy; Milo A Puhan; Martine Hoogendoorn; Rachel Garrod; Annemie M W J Schols; Brian Carlin; Roberto Benzo; Paula Meek; Mike Morgan; Maureen P M H Rutten-van Mölken; Andrew L Ries; Barry Make; Roger S Goldstein; Claire A Dowson; Jan L Brozek; Claudio F Donner; Emiel F M Wouters
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

View more
  80 in total

1.  Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.

Authors:  Mario Cazzola; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 2.  Optimizing bronchodilation in the prevention of COPD exacerbations.

Authors:  Marc Miravitlles; Antonio Anzueto; José R Jardim
Journal:  Respir Res       Date:  2017-06-20

Review 3.  Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

Authors:  Han Ni; Aung Htet; Soe Moe
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 4.  Rural and remote care: Overcoming the challenges of distance.

Authors:  Donna Goodridge; Darcy Marciniuk
Journal:  Chron Respir Dis       Date:  2016-02-21       Impact factor: 2.444

5.  Sex and gender considerations in Canadian clinical practice guidelines: a systematic review.

Authors:  Cara Tannenbaum; Barbara Clow; Margaret Haworth-Brockman; Patrice Voss
Journal:  CMAJ Open       Date:  2017-02-10

Review 6.  Medication Regimens for Managing COPD Exacerbations.

Authors:  Nirupama Putcha; Robert A Wise
Journal:  Respir Care       Date:  2018-06       Impact factor: 2.258

Review 7.  Pharmacogenomics of chronic obstructive pulmonary disease.

Authors:  Craig P Hersh
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

8.  ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum.

Authors:  Gaëtane C Michaud; Colleen L Channick; Anica C Law; Jessica B McCannon; MaryEllen Antkowiak; Garth Garrison; David Sayah; Richard H Huynh; Anna K Brady; Rosemary Adamson; Hilary DuBrock; Praveen Akuthota; Chad Marion; Charles Dela Cruz; James A Town; Başak Çoruh; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2016-07

9.  The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey.

Authors:  Young Seok Lee; Kyung Hoon Min; Chin Kook Rhee; Yong Hyun Kim; Seong Yong Lim; Soo-Jung Um; Chang-Hoon Lee; Ki-Suck Jung; Kwang Ha Yoo
Journal:  Lung       Date:  2019-03-11       Impact factor: 2.584

Review 10.  Patient Education Provided by Physiotherapists for Patients with Chronic Obstructive Pulmonary Disease: Results of a Scoping Review.

Authors:  Judy King; Sarah Tessier; Marie-Josée Charette; Danica Gaudet
Journal:  Physiother Can       Date:  2018       Impact factor: 1.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.